Literature DB >> 3022909

CA-125. Use as a tumor marker with mixed mesodermal tumors of the female genital tract.

W A Peters, C M Bagley, M R Smith.   

Abstract

CA-125 levels were determined in seven patients with a mixed mesodermal tumor of the ovary or endometrium. An elevated level was detected in five of six patients with metastatic or recurrent disease. Chemotherapy with cisplatin and Adriamycin (doxorubicin) resulted in a response in four patients, and the CA-125 level correlated well with the clinical status of the disease. Cisplatin/Adriamycin is an active combination in mixed mesodermal tumors and CA-125 appears to be a useful marker for following therapy.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3022909     DOI： 10.1002/1097-0142(19861215)58:12<2625::aid-cncr2820581213>3.0.co;2-a

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


  9 in total

1.  Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma.

Authors:  Gloria S Huang; Lydia G Chiu; Juliana S Gebb; Marc J Gunter; Paniti Sukumvanich; Gary L Goldberg; Mark H Einstein
Journal:  Gynecol Oncol       Date:  2007-10-23       Impact factor: 5.482

2.  Immunoscintigraphy using CA 125 antibodies in the management of ovarian cancer.

Authors:  J Brökelmann; A Bockisch; J Vogel; J Reinsberg; P Oehr; H J Biersack; D Krebs
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

3.  Rhizoctonia bataticola lectin induces apoptosis and inhibits metastasis in ovarian cancer cells by interacting with CA 125 antigen differentially expressed on ovarian cells.

Authors:  Prajna Hegde; Sindhura B R; Suhas Ballal; Bale M Swamy; Shashikala R Inamdar
Journal:  Glycoconj J       Date:  2021-11-08       Impact factor: 2.916

4.  Concurrent diagnosis of pulmonary metastasis of malignant mixed müllerian tumor and small cell lung cancer.

Authors:  Young Jin Lee; Eun Joo Jung; Seung Heon Lee; Young-Min Lee; Bomi Kim; Seok Jin Choi; Dae Hoon Jeong; Hyun-Kyung Lee
Journal:  Tuberc Respir Dis (Seoul)       Date:  2012-07-31

5.  Relationship of tumor marker CA125 and ovarian tumor stem cells: preliminary identification.

Authors:  Hui Zhang; Yongan Yang; Yifeng Wang; Xinping Gao; Weiming Wang; Hui Liu; Haipeng He; Yijuan Liang; Kun Pan; Hongli Wu; Junrong Shi; Huiling Xue; Ling Liang; Zhihuci Cai; Yanfang Fan; Yanyan Zhang
Journal:  J Ovarian Res       Date:  2015-03-28       Impact factor: 4.234

6.  Prolonged survival of a patient with pelvic recurrence of ovarian malignant mixed mullerian tumor after chemoradiotherapy.

Authors:  Fatemeh Homaei Shandiz; Sima Kadkhodayan; Malihe Hsanzade Mofrad; Zohre Yousefi Roodsari; Noorieh Sharifi Sistani; Majid Nabizadeh Marvast; Mahbobe Sadeghei
Journal:  Iran Red Crescent Med J       Date:  2014-09-05       Impact factor: 0.611

7.  Cancer antigen 125 is associated with disease status in uterine carcinosarcoma.

Authors:  Malcolm Strachan Ross; Chelsea Kilpatrick Chandler; Koji Matsuo; John Austin Vargo; Esther Elishaev; Nalyn Siripong; Jessica Layne Berger; Joseph Leo Kelley; Sarah Elizabeth Taylor
Journal:  Rare Tumors       Date:  2019-11-07

Review 8.  Exploring the role and diversity of mucins in health and disease with special insight into non-communicable diseases.

Authors:  Santosh Kumar Behera; Ardhendu Bhusan Praharaj; Budheswar Dehury; Sapna Negi
Journal:  Glycoconj J       Date:  2015-08-04       Impact factor: 3.009

9.  Comparisons of the survival time of patients with ovarian cancer adopting post-operative chemotherapy by use of paclitaxel combined with carboplatin or nedaplatin.

Authors:  Hongfei Gao; Lijun Yuan; Yimin Han
Journal:  World J Surg Oncol       Date:  2016-06-24       Impact factor: 2.754
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.